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Biomaterials in cartilage repair 
S. Nehrer, P. Vavken, R. Dorotka, Austria 
Autologous Chondrocyte Transplantation has revolutionized 
treatment options in cartilage defects in the last decade. The 
DMBTTJDUFDIOJRVFXJUIUIFQFSJPTUFBM¿BQIBTTPNFEJTBEWBOUBHFT
SFHBSEJOHUIFQFSJPTUFVNIBSWFTUBOE¾YBUJPOBTXFMMBTUIFWBSZJOH
biological properties of the periosteal tissue leading to hypertrophy 
and delamination of the graft impairing the clinical result. The 
development of biomaterials as a scaffold for cell transplantation 
allows a secure and reliable transport of the cells to the defect site to 
facilitate cartilage formation. Emerging research on the biomaterials 
has developed various kinds of materials, of which some are already 
in clinical use. The promising results of the new techniques will widen 
the indications for such methods and since there are less limitations 
in size, thickness and form biomaterials will allow the development 
of biological implants and open the way for a new paradigm in 
cartilage treatment from repair to regeneration. Cartilage is a 
USPVCMFTPNF UIJOH IBT CFFO SFBMJ[FE DFOUVSJFT BHP SF¿FDUJOH UIF
little intrinsic healing capabilities. Orthopedic surgeons have sought 
of numerous ways to treat this problem, ranging from resection 
techniques to highly sophisticated joint-resurfacing therapies. 
Frequently used methods on bring healthy cartilage tissue into the 
defect is by osteochondral transfer techniques, where osteochondral 
DZMJOEFST BSF QSFTT¾UUFE JOUP UIF EFGFDU TJUFXIJDI BSF IBSWFTUFE
from less loaded areas of the joint surface- Bobic and Hangody 
TQFDJ¾DTVSHJDBMJOTUSVNFOUTGPSTVDIQSPDFEVSFT	
#POFNBSSPX
stimulation techniques like microfracture are also commonly used 
	
IPXFWFSUIFTFUFDIOJRVFTZJFMEB¾CSPDBSUJMBHJOPVTSFQBJSUJTTVF
with questionable biomechanics in the long term (4). Autologous 
Chondrocyte Transplantation (ACT) was a new approach to the 
problem of cartilage defects by bringing cultured cell from harvested 
biopsies into the defect to provide chondrogenic cells to rgenerate 
the joint surface. Published in 1994 by Brittberg out of Lars Petersons 
HSPVQJUXBTUIF¾STUDFMMCBTFEUIFSBQZJOPSUIPQFEJDTBOEDIBOHFE
the paradigm of cartilage treatment from repair to rgeneration. 
&TQFDJBMMZJO&VSPQBUIFQFSJPTUFBM¿BQXBTSFQMBDFECZCJPNBUFSJBMT
and matrix “assisted” chondrocyte implantation methods were 
developed. Due to the restrictions in US long time no biomaterials 
XFSF JNQMFNFOUFE BOE KVTU SFDFOUMZ ¾STU USJBMT TUBSUFE "$5 IBT
advanced to its fourth generation referred to as matrix-associated 
"$5 *O UIJT QSPDFEVSF BSUJ¾DJBMMZ DPOTUSVDUFE DFMMCJPNBUFSJBM
compounds are implanted into defects. These tissue engineering 
applications were implanted to ultimately change the prognosis of 
cartilage defects (6), but still has to prove time in longterm controled 
studies. Autologous Chondrocyte Transplantation In ACT, pieces 
of cartilage (300-500 mg) are harvested from minor weightbearing 
areas of the joint surface. Chondrocytes are enzymatically isolated 
from these specimens and cultured in the laboratory. During a 
second operation, the cartilage defect is debrided and covered 
XJUIB¿BQPGUJCJBMQFSJPTUFVNTVUVSFEUPUIFSJNPGUIFEFGFDUBOE
TFBMFEXJUI¾CSJOHMVF"TVTQFOTJPOPGBQQSPYJNBUFMZNJMMJPO
cultured chondrocytes is injected into this bioactive chamber. The 
chondrocytes and the periosteum build a hyaline repair tissue, that 
approximates native cartilage. The precise interactions between the 
cells and the periosteum have been elucidated by Brutberg et al. 
reporting that there is reciprocal cytokine-mediated stimulation (7). 
Postoperatively, a rigorous regimen physiotherapy and of passive 
continous motion and 6 weeks of unloading with progression to full 
weightbearing at 10 to 12 weeks is ordered (8). In 1994, Britberg 
and coworkers published their results on 23 patients treated for 
cartilage defects with their new procedure (5). The results were very 
promising, yet depend on the location of the defect. 14 of 16 patients 
with condylar lesions had good to excellent results after two years. 
Patella lesions did not respond well to ACT. In 2000 Peterson et al. 
reported their 2- to 9-year results of 101 patients from a retrospective 
multicenter-study including arthroscopic, clinical, and histological 
evaluation. In this study ACT had good results in 92% for isolated 
condylar defects, 89% for osteochondritis dissecans, 67% for 
multiple condylar lesions, and 65% for patella lesions after 4.2 years 
of follow-up (7). The Genzyme Patient Registry Report documented 
improvement in comparison to baseline 85% for femoral lesions on 
patients after up to 4 years (9). Prospective studies compared ACT 
with microfracture, mosaicplasty, and OATS in clinical outcome, 
arthroscopy, and histological evaluation. In 2003 Bentley and 
colleagues presented their results from 100 patients treated with 
ACT (58 pts.) and mosaicplasty (42 pts.) (10). This group observed 
a favorable outcome after ACT in follow-up arthroscopy and clinical 
evaluation after 19 months. Horas et al. followed 40 patients treated 
with ACT or OATS (20:20) for two-years, reporting that patients with 
ACT lagged behind patients with OATS (11). Knutsen et al. compared 
 QBUJFOUT BGUFS "$5 PS NJDSPGSBDUVSF BOE GPVOE OP TJHOJ¾DBOU
difference after two years of follow-up (12). Limitations of ACT 
concerning the chondrocytes the main problems are associated with 
cell culture. Contamination is very rare, recorded for only 0.03% during 
cell processing and 0.16% at release for implantation, according to 
Genzyme data (9). Processing however has been shown to affect 
cellular performance and cryopreservation of cells deteriorates 
bioactivity as reported by Perka et al. (13) A major problem is cell-
dedifferentiation, a process during which chondrocytes loose their 
ability to build an appropriate tissue matrix. This process is caused 
by prolonged twodimensional culture, but can be reversed to some 
FYUFOU JO TQFDJ¾D DVMUVSF TZTUFNT 	
 1SPCMFNT BTTPDJBUFE
XJUIUIFQSPDFEVSFBOEUIFQFSJPTUFBM¿BQBSFSFQPSUFE*OUIF¾STU
studies of ACT, Peterson reported adverse events including 7 graft 
failures, 10 adhesions and 26 graft hypertrophies in 101 patients 
during 2- to 9-year follow-up (8). Genzyme reported adverse events 
in only 8%, and an cumulative incidence of treatment failure in 3.2% 
at 48 months (9). Nehrer et al. compared the histologic fmdings in 
18 patients with failed cartilage repair reporting graft delamination 
BOE IZQFSUSPQIZ PG UIF QFSJPTUFBM ¿BQ 	
 )ZQFSUSPQIZ XBT UIF
main reason for reoperation in ACT-treated patients in the Knutsen 
study (12). Summarized, most of the adverse effects are associated 
XJUI UIF QFSJPTUFBM ¿BQ XJUI JUT MJNJUBUFE TJ[F BOE QPTTJCJMJUZ PG
delamination and hypertrophy. On the other hand the periosteum 
has been shown to play a major role in the interaction with the 
implanted chondrocytes and tissue formation. Replacement of this 
¿BQSFRVJSFTBCJPNBUFSJBMUIBUBMTPTUJNVMBUFTDFMMQFSGPSNBODFJO
vivo. 
Biomaterials are an important part of tissue engineering therapies. In 
2000 E. Bell postulated the triad of tissue engineering consisting of 
the cell, the scaffold, and the signal (17). Biomaterials have been used 
to cover the debrided lesions instead of periosteum or as transport 
systems for the chondrocytes. In the latter isolated chondrocytes are 
cultured on these matrices in the laboratory, and the whole sponge-
like construct is placed into the defect; thus these materials facilitate 
the manipulation of the cells during the operation. Furthermore- and 
maybe even more important- the biomaterials provide biochemical 
and organizational cues for the chondrocytes to enhance cell growth 
and structured tissue deposition. It has been shown that both the 
chemical identity and the way in which the biomaterials are processed 
play a crucial role in cell behavior (18,19). Mechanically the matrix 
should have appropriate properties to be manipulated during the 
operation and to endure the mechanical loading during mobilization 
of the patient; generally the matrix has to replace the lost cartilage 
tissue until a new tissue is formed. Hence degradation has to be at a 
rate that matches the rate of tissue deposition by the chondrocytes; 
¾OBMMZCSFBLEPXOPGUIFNBUFSJBMIBTUPCFDPNQMFUFECVUOFJUIFS
toxic nor antigenic products are acceptable. There are three main 
types of biomaterials used as scaffolds for cartilage repair. (1.) 
Synthetic materials like polyglycolic- and polylactic- acid and 
copolymers, which have been used in surgery as suture material for 
MPOHUJNF5IFJSDIBSBDUFSJTUJDTBSFXFMMLOPXOBOEDBOCFNPEJ¾FE
at will. Their degradation products however are acidic and, in 
abundance, may cause damage to both native tissue and implanted 
cells. However new chemistry of these materials has improved their 
biocharacteristic and biocompatibility (2.) Hydrogels like agarose or 
alginate are very popular culture environments for in vitro cell culture 
ZFU MBDL PG TVG¾DJFOU NFDIBOJDBM SFTJTUBODF GPS JNQMBOUBUJPO 	

/BUVSBMQPMZNFSTMJLFDPMMBHFO¾CSJOPSIZBMVSPOJDBDJENFTIFTBSF
very promising biomaterials. The have impeccable biocompatibility, 
can be processed in a reliable and reproducible way and may 
enhance cell performance. Depending on material compostion 
and matrix architecture these scaffolds enhance the chondrocytic 
phenotype in the implanted cells (15,18-20). The use of cell-seeded 
matrices for ACT is widely used in Europe. There are copious names 
for this procedure: matrix-assisted, -augmented, -induced, matrix-
bound, and matrix-supported suggesting regulation; in the USA 
there is no FDA approval for matrices in human application. The most 
frequently used matrices are collagen scaffolds and hyaluronic acid 
meshes. A collagen matrix (Chondroguide®, Geistlich Biomaterials, 
Wollhusen, Switzerland) that has been developed as a substitute for 
UIFQFSJPTUFBM¿BQJTOPXVTFEBTBDFMMTFFEFETDBGGPMEGPSDBSUJMBHF
repair. Haddo et al., Cherubin et al., and Behrens et al. reported 
satisfying results with Chondroguide (21-25). Another biomaterial 
commonly used as matrix is hyaluronic acid (HA). Hyaluronate 
injections have been used in the management of osteoarthrosis 
	
 BOE JU JT LOPXO UIBU DIPOESPDZUFTIBWFIZBMVSPOBUFTQFDJ¾D
surface receptors (CD 44) (27). Preclinical in vitro and animal 
studies evaluated HA-meshes (28). Clinical application in humans 
started in 1999 in Italy (29). Our own results on patients treated with 
chondrocyte-seeded hyaluronate are presented below. 
Matrixassisted Chondrocyte Transplantation: selected clinical 
results. Hyaloronan Matrix (Hyalograft C, Fidia) Patients underwent 
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arthroscopy and cartilage was harvested and sent to the GLP 
laboratory at FAB, Abbano, Italy. Chondrocytes are isolated and 
cultured on the hyaluronate mesh one week prior to surgery. 4 
to 6 weeks after arthroscopy the patients are reoperated and the 
NBUSJYJTJNQMBOUFE5IFHSBGUJTBUUBDIFEJOUPUIFEFGFDUBOE¾YFE
XJUI¾CSJO HMVF UIVT UIFOFFE GPS TVUVSFT JT PCWJBUFEBOEPOMZ B
minimal incision is needed and even arthroscopic implantation is 
possible. 36 patients were treated with Hyalograft in the knee and 
included in a prospective study (30). The average age of the patients 
was 33 years (range 14-54), the male-female ratio was 17:19 and 
the lesion size was 1,5-8 cm². A three year follow-up of the patients 
reveald minor adverse events in 3 patients with persistent effusion 
and one week of moderate fever, all adverse events resolved and 
no treatment was necessary. The patients also included complex 
lesions with associated ligament or meniscus injury, and 3 patients 
were undergoing chondrocyte transplantation as a salvage 
operation instead of arthroplasty. Preliminary clinical evaluation 
with the Lysholm score revealed an average improvement to 80,8 
postoperative compared with 57 preoperative. For the singular 
lesions - the classic indication for ACT - there was an improvement 
from 57 to 94. All patients with salvage operations had to be 
provided with a knee prosthesis within two years, 2 patients had 
only moderate improvement due to systemic disease (Psoriasis 
and Crohn’s disease) Fibrinmatrix (Biocart 2, Prochon) Fibrin as a 
natural constituent of the bloodclot can be considered as the natural 
TDBGGPME PG XPVOE IFBMJOH )PNPMPH ¾CSJO XJUI UIF BEEJUJPO PG
little amounts of hyaluronan can be produced as a gel-like matrix 
and serve as a scaffold for cell transplantation. A small series of 8 
patients in a saftey and feasability study showed very good results at 
one year in single contained defects in the knee. Collagengel (CaRes, 
Arthro Kinetics) Collagengel forms a three dimensional matrix to 
preserve the chondrocytic phenotype of the transplanted cells. In 
the CaRes system the chondrocytes are immediately embedded 
in the gel after isolation, which does not allow dedifferentiation of 
the cells, however for that reason the cell yield is less at the time of 
implantation. CaRes has shown simmilar results to ACT in a smaller 
study and good results in a multicenter trial that has recently been 
presented (Schneider et al.) 
Results of preclincal and clinical studies of ACT combined with 
biomaterials are encouraging. Given an appropriate indication, 
in singular chondral defect or in OD, the results are equal to the 
“classic” ACT. Associated ligament or meniscus injuries complicate 
the procedure. Generalized osteoarthrosis is not amenable 
to ACT, with or without biomaterial support. More than 3500 
patients treated with hyaluronate scaffolds prove the safety of 
the procedure; approximately 400 patients have been reviewed 
for published studies. The presented fmdings were promising and 
indicated that this procedure is a very valuable means of cartilage 
repair. Collagenous membranes and matrices have been used as a 
TVCTUJUVUFGPSUIFQFSJPTUFBM¿BQTBOEBTTDBGGPMEGPSDIPOESPDZUFT
Again clinical studies reported reassuring results on their patients. 
0UIFS CJPNBUFSJBMT MJLF ¾CSJO TDBGGPMET BSF PCKFDUJWF PG JOUFOTJWF
research, yet evidence is still scarce. However, none of these polymers 
has been long-term studied thus far. Prospective long-term clinicial 
trials are needed before these biomaterials should be considered 
for clinical routine. Furthermore the matrix-associated ACT has to be 
compared with the classical ACT. It has to be emphasized that ACT is 
not indicated in degenerative joint disease. ACT has its place in the 
management of confmed unicompartimental chondral injuries. Its use 
for other indications will yield poor results. The use of biomaterials 
in ACT allows safe and standardized transplantation of cultured 
autologous cells for cartilage repair. The long-term consideration 
is to broaden the indications for cell-based therapies and to delay 
or avoid the need for arthroplasty. Hence systematic research and 
regulations are needed to guarantee the patients safety and to 
support the development of detailed techniques. For the future the 
management of cartilage defects repair and replacement will be 
substituted by a biological regeneration. 
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19.1
Cells culture in lumbar disc disease 
H.J. Meisel1, T. Ganey2, C. Hohaus1, Y. Minkus1, J. Libera1, O. Josimovic-
Alasevic1, W. Hutton2, 1Germany, 2United States of America 
Low back pain is an extremely common symptom, affecting nearly 
three-quarters of the population sometime in their life. While 90% 
of the population recovers within 3 months, in some patients chronic 
back or leg pain leads to long term physical disability and a reduced 
quality of life. Disc anatomy would be expected to play a pivotal role 
in the underlying pain, yet abnormal spine and disc morphology 
including disc herniation has been described as a normal component 
of an asymptomatic population. Why is it that some patients remain 
asymptomatic, and is it possible to treat patients with degenerative 
change that become symptomatic? Given that disc herniation is 
thought to be an extension of progressive disc degeneration that 
attends the normal aging process, seeking an effective therapy that 
staves disc degeneration has been considered a logical attempt to 
reduce back pain. Previous studies have validated genetic factors, and 
implicated nutrition as relevant to the degenerative process. However, 
the high prevalence across diverse populations suggests that a 
NZSJBEPGVOJEFOUJ¾FEGBDUPSTMJLFMZDPOUSJCVUFUPTJNJMBSTZNQUPNT
As no effective therapies to retard or reverse disc degeneration 
have yet been devised, a variety of surgical procedures have been 
developed to treat disc degeneration and back pain. Unfortunately, 
the procedures currently available fail to offer an outcome that is 
prosthetic and at the same time physiologic. Surgery tends to limit 
motion, and fusion in particular seems to shunt excessive stresses 
to adjacent spinal segments. Equally concerning in selecting fusion 
as an option is the fact that non-unions have been reported in 5-35% 
of patients, and that patients undergoing a repeat fusion for failed 
surgery in the lumbar spine may still have a clinical failure rate as 
high as 40%. The advent of tissue engineering has broadened the 
options for considering treatments that tailor repair to distinct 
anatomy. In particular, the use of cell and gene therapy to endow 
TQFDJ¾D QSPQFSUJFT PS SFQBJS TQFDJ¾D UJTTVFT JT XJEFMZ DPOTJEFSFE
BO FNFSHJOHNPEBMJUZ GPS FGGFDUJOH USFBUNFOU /VNFSPVT TDJFOUJ¾D
studies have provided observations concerning the biochemistry 
and biomechanics of the disc, offering insights and theories into 
structure-function-failure relationships. The most apparent cellular 
and biochemical changes attributable to degeneration include a 
decrease in cell density in the disc that is accompanied by a reduction 
JOTZOUIFTJTPGDBSUJMBHFTQFDJ¾DFYUSBDFMMVMBSNBUSJYDPNQPOFOUTTVDI
as Type II collagen and aggrecan. As the proteoglycan content of the 
disc decreases, the resulting loss of water-binding capacity by the disc 
matrix coupled with a subsequent reduced capacity for dissipating 
spinal forces are thought to lead to disc disease. Collagen plays a key 
load-bearing role in the disc, and changes in its extracellular matrix 
content have been attributed to aging as well as to the pathology of 
degeneration. In normal intervertebral discs, at least seven different 
types of collagen are present (i.e., Types I, II, III, V, VI, IX, and XI), 
BMUIPVHI5ZQFT*BOE**BSFUIFNPTUBCVOEBOU5IFBOVMVT¾CSPTVT
contains more Type I collagen than Type II, whereas the nucleus 
QVMQPTVTJTDPNQPTFENBJOMZPG5ZQF**DPMMBHFO$BMDJ¾DBUJPOPGUIF
vertebral endplates is another factor thought to be relevant to disc 
degeneration. The passage of nutrients and waste products across 
UIFFOEQMBUFEFQFOETPO¿VJE¿PXJOHJOUPUIFEJTD	EVSJOHUIFOJHIU
BUCFESFTU
BOE¿PXJOHPVUEVSJOHUIFEBZXIFOXFXBMLBCPVU5IVT
shortcomings of permeability would be expected to adversely effect 
chondrocyte metabolism. While cells constitute only 1% of the adult 
disc tissue by volume, their role in matrix synthesis and metabolic 
turnover is vital. Most assessments of intervertebral disc failure 
have focused on degenerative, morphologic changes in disc tissue 
morphology that affect the biomechanical performance of the motion 
segment. In this consideration, mechanical failure is little more than 
a corollary of matrix structure, which in turn depends on balanced 
DFMMNFUBCPMJTN GPSFG¾DJFOUNBJOUFOBODFPG UIFEJTDNBUSJY(JWFO
the value of cells to the metabolic health of the disc, one therapeutic 
strategy would be to either replace, regenerate, or augment the 
intervertebral disc cell population, with a goal of correcting matrix 
JOTVG¾DJFODJFTBOESFTUPSJOHOPSNBMTFHNFOUCJPNFDIBOJDT3FDFOU
work has shown that disc aging and degeneration are accompanied 
by a decline in the number of cells in the disc, a change attributable 
to both necrosis and apoptosis. Perhaps a more important outcome 
of this work and that of others has been to demonstrate that disc 
chondrocytes retain an ability to respond to both genetic endowment 
and appropriate in vivo stimulation, and that when returned to the 
disc under controlled conditions integrate with the surrounding 
tissue. With this in mind, we designed a study (using the dog as our 
model) to investigate the hypothesis that 1) repair of the damaged 
disc is technically feasible, 2) autologous cells can be reproducibly 
DVMUVSFEVOEFSEF¾OFEBOEDPOUSPMMFEDPOEJUJPOT
QFSDVUBOFPVT
delivery is possible, and that 4.) disc chondrocytes will integrate with 
